IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma

Human Pathology

Volumn 44, Issue 10, 2013, Pages 2167-2172

  Tang, Hongping ^a   Wei, Qingzhu ^b   Ge, Juan ^a   Jian, Wenjing ^a   Liu, Jiangchuan ^b   Zhong, Lin ^b   Fu, Bo ^b   Zhao, Tong ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Hodgkin and Reed Sternberg cell; Hodgkin lymphoma; Immunohistochemistry; IMP3

Indexed keywords

CD15 ANTIGEN; CD30 ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; TRANSCRIPTION FACTOR PAX5;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PRESCHOOL CHILD; PROTEIN EXPRESSION; REED STERNBERG CELL; SCHOOL CHILD; STAINING;

BIOMARKER; HODGKIN AND REED-STERNBERG CELL; HODGKIN LYMPHOMA; IMMUNOHISTOCHEMISTRY; IMP3;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD30; CHILD; CHILD, PRESCHOOL; CYTOPLASM; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; REED-STERNBERG CELLS; REPRODUCIBILITY OF RESULTS; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84884414066     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.04.011     Document Type: Article

References (32)

1. S.H. Swerdlow, E. Campo, and N.L. Harris WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues 4th ed. 2008 IARC Press Lyon
2. P. Seam, J.E. Janik, D.L. Longo, and V.T. Devita Jr. Role of chemotherapy in Hodgkin's lymphoma Cancer J 15 2009 150 154
3. B. Klimm, and A. Engert Combined modality treatment of Hodgkin's lymphoma Cancer J 15 2009 143 149
4. L.R. Jakovic, B.S. Mihaljevic, M.D. Perunicic Jovanovic, A.D. Bogdanovic, B.M. Andjelic, and V.Z. Bumbasirevic The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma Leuk Lymphoma 52 2011 1913 1919
5. H. Stein, and M. Hummel Cellular origin and clonality of classic Hodgkin's lymphoma: immunophenotypic and molecular studies Semin Hematol 36 1999 233 241
6. P. Browne, K. Petrosyan, A. Hernandez, and J.A. Chan The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma Am J Clin Pathol 120 2003 767 777
7. M. Hummel, K. Ziemann, H. Lammert, S. Pileri, E. Sabattini, and H. Stein Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells N Engl J Med 333 1995 901 906
8. R. Küppers, and K. Rajewsky The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease Annu Rev Immunol 16 1998 471 493
9. M. Müschen, K. Rajewsky, and A. Bräuninger Rare occurrence of classical Hodgkin's disease as a T cell lymphoma J Exp Med 191 2000 387 394
10. N.S. Aguilera, J. Chen, and K.E. Bijwaard Gene rearrangement and comparative genomic hybridization studies of classic Hodgkin lymphoma expressing T-cell antigens Arch Pathol Lab Med 130 2006 1772 1779
11. R.A. Higgins, J.E. Blankenship, and M.C. Kinney Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma Arch Pathol Lab Med 132 2008 441 461
12. W.S. Chu, S.L. Abbondanzo, and G. Frizzera Inconsistency of the immunophenotype of Reed-Sternberg cells in simultaneous and consecutive specimens from the same patients Am J Pathol 141 1992 11 17
13. M.A. Vasef, R. Alsabeh, L.J. Medeiros, and L.M. Weiss Immunophenotype of Reed-Sternberg and Hodgkin's cells in sequential biopsy specimens of Hodgkin's disease Am J Clin Pathol 108 1997 54 59
14. G. Horne, S.A. Medlicott, A. Mansoor, J. Lategan, R. Lai, and P. Beck A definitive diagnosis of primary Hodgkin lymphoma on endoscopic biopsy material utilizing in-depth immunohistochemical analysis Can J Gastroenterol 21 2007 185 188
15. M.M. Desouki, G.R. Post, D. Cherry, and J. Lazarchick PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms Clin Med Res 8 2010 84 88
16. R. Herbeck, D. Teodorescu Brînzeu, M. Giubelan, E. Lazǎr, A. Dema, and H. Ioniţǎ B-cell transcription factors Pax-5, Oct-2, BOB.1, Bcl-6, and MUM1 are useful markers for the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma Rom J Morphol Embryol 52 2011 69 74
17. J. Nielsen, J. Christiansen, J. Lykke-Andersen, A.H. Johnsen, U.M. Wewer, and F.C. Nielsen A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development Mol Cell Biol 19 1999 1262 1270
18. F. Mueller-Pillasch, U. Lacher, and C. Wallrapp Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein Oncogene 14 1997 2729 2733
19. F. Mueller-Pillasch, B. Pohl, and M. Wilda Expression of the highly conserved RNA binding protein KOC in embryogenesis Mech Dev 88 1999 95 99
20. D. Lu, P. Vohra, P.G. Chu, B. Woda, K.L. Rock, and Z. Jiang An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia Am J Surg Pathol 33 2009 521 525
21. D.L. Wachter, G. Kristiansen, and C. Soll Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value Histopathology 60 2012 278 286
22. S. Vranic, O. Gurjeva, S. Frkovic-Grazio, J. Palazzo, O. Tawfik, and Z. Gatalica IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast Appl Immunohistochem Mol Morphol 19 2011 413 416
23. M. Shi, A.E. Fraire, and P. Chu Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation Am J Surg Pathol 35 2011 878 882
24. H.G. Li, J.J. Han, Z.Q. Huang, L. Wang, W.L. Chen, and X.M. Shen IMP3 is a novel biomarker to predict metastasis and prognosis of tongue squamous cell carcinoma J Craniofac Surg 22 2011 2022 2025
25. O. Walter, M. Prasad, S. Lu, R.M. Quinlan, K.L. Edmiston, and A. Khan IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype Hum Pathol 40 2009 1528 1533
26. D. Li, D. Yan, and H. Tang IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis Ann Surg Oncol 16 2009 3499 3506
27. K. Ikenberg, F.R. Fritzsche, and U. Zuerrer-Haerdi Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores BMC Cancer 10 2010 341
28. A. Copeland, and A. Younes Current treatment strategies in Hodgkin lymphomas Curr Opin Oncol 24 2012 466 474
29. J.F. García, M. Mollejo, and M. Fraga Large B-cell lymphoma with Hodgkin's features Histopathology 47 2005 101 110
30. R.L. King, T. Pasha, M.R. Roullet, P.J. Zhang, and A. Bagg IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue Hum Pathol 40 2009 1699 1705
31. E.M. Hartmann, S. Beà, and A. Navarro Increased tumor cell proliferation in mantle cell lymphoma is associated with elevated insulin-like growth factor 2 mRNA-binding protein 3 expression Mod Pathol 25 2012 1227 1235
32. R. Küppers The biology of Hodgkin's lymphoma Nat Rev Cancer 9 2009 15 27